These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8956629)

  • 1. Confounding by indication and channeling over time: the risks of beta 2-agonists.
    Blais L; Ernst P; Suissa S
    Am J Epidemiol; 1996 Dec; 144(12):1161-9. PubMed ID: 8956629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re: "Confounding by indication and channeling over time: the risks of beta2-agonists".
    Pearce N; Beasley R; Crane J; Burgess C
    Am J Epidemiol; 1997 Nov; 146(10):885-7. PubMed ID: 9384211
    [No Abstract]   [Full Text] [Related]  

  • 3. Confounding by severity does not explain the association between fenoterol and asthma death.
    Beasley R; Burgess C; Pearce N; Woodman K; Crane J
    Clin Exp Allergy; 1994 Jul; 24(7):660-8. PubMed ID: 7953948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists.
    Suissa S; Ernst P; Boivin JF; Horwitz RI; Habbick B; Cockroft D; Blais L; McNutt M; Buist AS; Spitzer WO
    Am J Respir Crit Care Med; 1994 Mar; 149(3 Pt 1):604-10. PubMed ID: 8118625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent trends in the use of inhaled beta 2-adrenergic agonists and inhaled corticosteroids in Saskatchewan.
    Habbick B; Baker MJ; McNutt M; Cockcroft DW
    CMAJ; 1995 Nov; 153(10):1437-43. PubMed ID: 7585370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity.
    Garrett JE; Lanes SF; Kolbe J; Rea HH
    Thorax; 1996 Nov; 51(11):1093-9. PubMed ID: 8958891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term effects of inhaled beta 2-agonists on bronchial hyperresponsiveness in asthmatics].
    Ogawa C; Sano Y
    Nihon Rinsho; 1996 Nov; 54(11):3081-6. PubMed ID: 8950959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of beta-agonists and the risk of death and near death from asthma.
    Spitzer WO; Suissa S; Ernst P; Horwitz RI; Habbick B; Cockcroft D; Boivin JF; McNutt M; Buist AS; Rebuck AS
    N Engl J Med; 1992 Feb; 326(8):501-6. PubMed ID: 1346340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse effects of beta-agonists: are they clinically relevant?
    Abramson MJ; Walters J; Walters EH
    Am J Respir Med; 2003; 2(4):287-97. PubMed ID: 14719995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and side effects of beta 2-agonists by inhaled route in acute asthma in children: comparison of salbutamol, terbutaline, and fenoterol.
    Scalabrin DM; Solé D; Naspitz CK
    J Asthma; 1996; 33(6):407-15. PubMed ID: 8968295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International trends in sales of inhaled fenoterol, all inhaled beta-agonists, and asthma mortality, 1970-1992.
    Lanes SF; Birmann B; Raiford D; Walker AM
    J Clin Epidemiol; 1997 Mar; 50(3):321-8. PubMed ID: 9120532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case-control study of salmeterol and near-fatal attacks of asthma.
    Williams C; Crossland L; Finnerty J; Crane J; Holgate S; Pearce N; Beasley R
    Thorax; 1998 Jan; 53(1):7-13. PubMed ID: 9577515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical complexity and epidemiologic uncertainty in case-control research. Fenoterol and asthma management.
    Horwitz RI; Spitzer W; Buist S; Cockcroft D; Ernst P; Habbick B; Hemmelgarn B; McNutt M; Rebuck AS; Suissa S
    Chest; 1991 Dec; 100(6):1586-91. PubMed ID: 1959400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The severity of asthma in relation to beta agonist prescribing.
    Garrett JE; Turner P
    N Z Med J; 1991 Feb; 104(905):39-40. PubMed ID: 1671713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the extent and duration of hypokalaemia following three nebulized beta 2-adrenoceptor agonists.
    Burgess CD; Flatt A; Siebers R; Crane J; Beasley R; Purdie G
    Eur J Clin Pharmacol; 1989; 36(4):415-7. PubMed ID: 2567672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-effect relationship of the beta-agonists fenoterol and salbutamol in patients with asthma.
    Newhouse MT; Dolovich MB; Kazim F
    Chest; 1994 Jun; 105(6):1738-42. PubMed ID: 8205869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rise and fall of asthma-related mortality in Italy and sales of beta2-agonists, 1980-1994.
    Romano F; Recchia G; Staniscia T; Bonitatibus A; Villa M; Nicolosi A; De Carli G; Mannino S
    Eur J Epidemiol; 2000; 16(9):783-7. PubMed ID: 11297218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optical illusions from visual data analysis: example of the New Zealand asthma mortality epidemic.
    Suissa S; Ernst P
    J Clin Epidemiol; 1997 Oct; 50(10):1079-88. PubMed ID: 9368515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pulmonary and extrapulmonary effects of inhaled beta-agonists in patients with asthma.
    Windom HH; Burgess CD; Siebers RW; Purdie G; Pearce N; Crane J; Beasley R
    Clin Pharmacol Ther; 1990 Sep; 48(3):296-301. PubMed ID: 1976051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology.
    Sears MR; Taylor DR
    Drug Saf; 1994 Oct; 11(4):259-83. PubMed ID: 7848546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.